Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses-Reference-Cited by-同舟云学术

Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses

Published:2016-01-22 Issue:3 Volume:59 Page:1003-1020
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Demont Emmanuel H.¹,Bailey James M.¹,Bit Rino A.¹,Brown Jack A.¹,Campbell Colin A.¹,Deeks Nigel¹,Dowell Simon J.¹,Eldred Colin¹,Gaskin Pam¹,Gray James R. J.¹,Haynes Andrea¹,Hirst David J.¹,Holmes Duncan S.¹,Kumar Umesh¹,Morse Mary A.¹,Osborne Greg J.¹,Renaux Jessica F.¹,Seal Gail A. L.¹,Smethurst Chris A.¹,Taylor Simon¹,Watson Robert¹,Willis Robert¹,Witherington Jason¹

Affiliation:

1. Immuno Inflammation Therapeutic Area Unit, and ‡Platform Technology and Science, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01512

Reference44 articles.

1. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

2. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, Fingolimod will change therapeutic paradigm approach

3. Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases